A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children

Vaccine

Volumn 34, Issue 6, 2016, Pages 714-722

  Stassijns, Jorgen ^a   Bollaerts, Kaatje ^a   Baay, Marc ^a   Verstraeten, Thomas ^a  

^a Epidemiology and Pharmacovigilance Consulting and Services   (Belgium)

Author keywords

Adjuvants; Children; Safety; Vaccine

Indexed keywords

INFLUENZA VACCINE; MALARIA VACCINE; ADJUVANT SYSTEM 01; ALPHA TOCOPHEROL; ASO2A ADJUVANT; ASO3B ADJUVANT; DRUG COMBINATION; IMMUNOLOGICAL ADJUVANT; LIPID A; MF59 OIL EMULSION; POLYSORBATE; SAPONIN; SQUALENE; VACCINE;

ALOPECIA AREATA; ATTENTION DEFICIT DISORDER; CHILD; CHILD SAFETY; CHRONIC DISEASE; CONVULSION; DROWSINESS; DRUG SAFETY; ERYTHEMA; FEBRILE CONVULSION; FEVER; GASTROENTERITIS; GLOMERULONEPHRITIS; HUMAN; HYPERSENSITIVITY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFLUENZA; IRRITABILITY; LOSS OF APPETITE; MALARIA; MENINGITIS; META ANALYSIS; MULTICENTER STUDY (TOPIC); PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN ALLERGY; SWELLING; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; INFANT; PRESCHOOL CHILD; RISK; STATISTICAL MODEL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ALPHA-TOCOPHEROL; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HUMANS; INFANT; LIKELIHOOD FUNCTIONS; LIPID A; POLYSORBATES; RISK; SAPONINS; SQUALENE; VACCINES;

EID: 84958752273     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.024     Document Type: Review

References (59)

1. Garcon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10(4):471-486.
2. Alving C.R., Rao M., Steers N.J., Matyas G.R., Mayorov A.V. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines 2012, 11(6):733-744.
3. Fox C.B., Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013, 12(7):747-758.
4. World Health Organization Pandemic influenza A (H1N1) 2009 virus vaccine - conclusions and recommendations from the october 2009 meeting of the immunization Strategic Advisory Group of experts. Wkly Epidemiol Rec 2009, 84(49):505-516.
5. Pellegrini M., Nicolay U., Lindert K., Groth N., Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009, 27(49):6959-6965.
6. Vekemans J., Guerra Y., Lievens M., Benns S., Lapierre D., Leach A., et al. Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials. Hum Vaccines 2011, 7(12):1309-1316.
7. Wijnans L., de Bie S., Dieleman J., Bonhoeffer J., Sturkenboom M. Safety of pandemic H1N1 vaccines in children and adolescents. Vaccine 2011, 29(43):7559-7571.
8. Yin J.K., Khandaker G., Rashid H., Heron L., Ridda I., Booy R. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respir Viruses 2011, 5(5):299-305.
9. Manzoli L., De Vito C., Salanti G., D'Addario M., Villari P., Ioannidis J.P. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. PLoS ONE 2011, 6(9):e24384.
10. Tsai T.F. MF59 adjuvanted seasonal and pandemic influenza vaccines. Yakugaku zasshi: J Pharm Soc Jpn 2011, 131(12):1733-1741.
11. Ruiz-Aragon J., Grande Tejada A.M., Marquez-Pelaez S., Molina Linde J.M., Yang R. Assessment of the MF59-adjuvanted pandemic influenza A/H1N1 vaccine. Systematic review of literature. An Pediatr (Barc, Spain) 2013, 79(4):208-217.
12. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558.
13. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
14. Macete E., Aponte J.J., Guinovart C., Sacarlal J., Ofori-Anyinam O., Mandomando I., et al. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop Med Int Health 2007, 12(1):37-46.
15. Bojang K.A., Olodude F., Pinder M., Ofori-Anyinam O., Vigneron L., Fitzpatrick S., et al. Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children. Vaccine 2005, 23(32):4148-4157.
16. Aide P., Aponte J.J., Renom M., Nhampossa T., Sacarlal J., Mandomando I., et al. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS ONE 2010, 5(11):e13838.
17. Aponte J.J., Aide P., Renom M., Mandomando I., Bassat Q., Sacarlal J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007, 370(9598):1543-1551.
18. Sacarlal J., Aide P., Aponte J.J., Renom M., Leach A., Mandomando I., et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis 2009, 200(3):329-336.
19. Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., Olivier A., et al. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. PLoS ONE 2010, 5(11):e14090.
20. Abdulla S., Salim N., Machera F., Kamata R., Juma O., Shomari M., et al. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region. Malar J 2013, 12:11.
21. Agnandji S.T., Asante K.P., Lyimo J., Vekemans J., Soulanoudjingar S.S., Owusu R., et al. Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization. J Infect Dis 2010, 202(7):1076-1087.
22. Owusu-Agyei S., Ansong D., Asante K., Kwarteng Owusu S., Owusu R., Wireko Brobby N.A., et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 2009, 4(10):e7302.
23. Agnandji S.T., Lell B., Soulanoudjingar S.S., Fernandes J.F., Abossolo B.P., Conzelmann C., et al. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 2011, 365(20):1863-1875.
24. Agnandji S.T., Lell B., Fernandes J.F., Abossolo B.P., Methogo B.G., Kabwende A.L., et al. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 2012, 367(24):2284-2295.
25. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014, 11(7):e1001685.
26. Thera M.A., Doumbo O.K., Coulibaly D., Laurens M.B., Kone A.K., Guindo A.B., et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. PLoS ONE 2010, 5(2):e9041.
27. Withers M.R., McKinney D., Ogutu B.R., Waitumbi J.N., Milman J.B., Apollo O.J., et al. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children. PLoS Clin Trials 2006, 1(7):e32.
28. Thera M.A., Doumbo O.K., Coulibaly D., Laurens M.B., Ouattara A., Kone A.K., et al. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 2011, 365(11):1004-1013.
29. Ogutu B.R., Apollo O.J., McKinney D., Okoth W., Siangla J., Dubovsky F., et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 2009, 4(3):e4708.
30. Idoko O.T., Owolabi O.A., Owiafe P.K., Moris P., Odutola A., Bollaerts A., et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial. Tuberculosis (Edinb, Scotl) 2014, 94(6):564-578.
31. Waddington C., Andrews N., Hoschler K., Walker W., Oeser C., Reiner A., et al. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age. Health Technol Assess (Winch, Engl) 2010, 14(46):1-130.
32. Langley J.M., Scheifele D.W., Quach C., Vanderkooi O.G., Ward B., McNeil S., et al. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Vaccine 2012, 30(23):3389-3394.
33. Diez-Domingo J., Garces-Sanchez M., Baldo J.M., Planelles M.V., Ubeda I., JuBert A., et al. Immunogenicity and safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase II, randomized, open, controlled study. Pediatr Infect Dis J 2010, 29(6):e35-e46.
34. Diez-Domingo J., Baldo J.M., Planelles-Catarino M.V., Garces-Sanchez M., Ubeda I., Jubert-Rosich A., et al. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination. Influenza Other Respir Viruses 2015, 9(2):68-77.
35. Nolan T., Roy-Ghanta S., Montellano M., Weckx L., Ulloa-Gutierrez R., Lazcano-Ponce E., et al. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis 2014, 210(4):545-557.
36. Johnson C., Hohenboken M., Poling T., Jaehnig P., Kanesa-Thasan N. Safety and immunogenicity of cell culture-derived A/H3N2 variant influenza vaccines: a phase I randomized, observer-blind, dose-ranging study. J Infect Dis 2014.
37. Block S.L., Ruiz-Palacios G.M., Guerrero M.L., Beygo J., Sales V., Holmes S.J. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. Pediatr Infect Dis J 2012, 31(7):e92-e98.
38. Nassim C., Christensen S., Henry D., Holmes S., Hohenboken M., Kanesa-Thasan N. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to <9 years of age. Pediatr Infect Dis J 2012, 31(4):e59-e65.
39. Arguedas A., Soley C., Abdelnour A., Sales V., Lindert K., Della Cioppa G., et al. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum Vaccines 2011, 7(1):58-66.
40. Knuf M., Leroux-Roels G., Rumke H.C., Abarca K., Rivera L., Lattanzi M., et al. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age. Pediatr Infect Dis J 2014, 33(12):e320-e329.
41. Knuf M., Leroux-Roels G., Rumke H.C., Abarca K., Rivera L., Lattanzi M., et al. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age. Vaccine 2015, 33(1):174-181.
42. Della Cioppa G., Vesikari T., Sokal E., Lindert K., Nicolay U. Trivalent and quadrivalent MF59((R))-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine 2011, 29(47):8696-8704.
43. Vesikari T., Pellegrini M., Karvonen A., Groth N., Borkowski A., O'Hagan D.T., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28(7):563-571.
44. Solares A.R., Aragon C.G., Pivaral R.U., Prado-Cohrs D., Sales-Carmona V., Pellegrini M., et al. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children. J Infect Dev Ctries 2014, 8(9):1160-1168.
45. Zedda L., Forleo-Neto E., Vertruyen A., Raes M., Marchant A., Jansen W., et al. Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age. Pediatr Infect Dis J 2015, 34(1):73-78.
46. Vesikari T., Knuf M., Wutzler P., Karvonen A., Kieninger-Baum D., Schmitt H.J., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365(15):1406-1416.
47. Nolan T., Bravo L., Ceballos A., Mitha E., Gray G., Quiambao B., et al. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children. Vaccine 2014, 32(46):6146-6156.
48. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009, 6(7):e1000097.
49. Garcia-Sicilia J., Gillard P., Carmona A., Tejedor J.C., Aristegui J., Merino J.M., et al. Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 2011, 29(26):4353-4361.
50. Langley J.M., Reich D., Aggarwal N., Connor D., Lebel M.H., Gupta A., et al. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. Pediatr Infect Dis J 2012, 31(8):848-858.
51. Black S., Della Cioppa G., Malfroot A., Nacci P., Nicolay U., Pellegrini M., et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 2010, 28(45):7331-7336.
52. European Medicines Agency Withdrawal assessment report, fluad pediatric influenza vaccine, surface antigen, inactivated, adjuvanted with MF59C 2013.
53. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015.
54. European Medicines Agency Twenty-second pandemic pharmacovigilance update. London 2010.
55. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7(3):e33536.
56. European Centre for Disease Prevention and Control Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation) Stockholm 2012.
57. Barker C.I., Snape M.D. Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infect Dis 2014, 14(3):227-238.
58. Banzhoff A., Haertel S., Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccines 2011, 7(5):539-548.
59. Tsai T., Del Giudice G., Crucitti A., Weil J., Narasimhan V. Is the adjuvant solely to blame?. BMJ 2013, 346:2375.